Drugs / JNJ-64042056
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06544616 | Jul 2024 → Dec 2026 expected | Alzheimer disease | Janssen Pharmaceutica N.V., Belgium | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-09-25 | AC Immune SA | Results Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine acimmune.com ↗
ACI-35.030 generated a rapid, robust and durable polyclonal response against pathological forms of Tau including phosphorylated Tau (pTau) and brain-derived Tau (enriched paired helical filament, ePHF). |
| 2024-07-25 | AC Immune SA | Regulatory AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease acimmune.com ↗
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its active-immunotherapy candidate, ACI-35.030 (now called JNJ-2056), targeting the pathologic form of the Tau protein, phosphorylated Tau (pTau), has received Fast Track designation from the U.S. Food and Drug Administration (FDA). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-25 | AC Immune SA | Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine acimmune.com ↗ |
| 2024-07-25 | AC Immune SA | AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease acimmune.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-64042056 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06544616 ↗ |
| Route | Intramuscular | “JNJ-64042056 will be administered intramuscularly.” NCT06544616 ↗ |